Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen

被引:115
作者
Conlan, JW [1 ]
Shen, H [1 ]
Webb, A [1 ]
Perry, MB [1 ]
机构
[1] Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0C6, Canada
关键词
O-polysaccharide; Francisella tularensis; bovine serum albumin;
D O I
10.1016/S0264-410X(02)00345-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The purpose of this study was to evaluate the efficacy of a vaccine consisting of the O-polysaccharide of the lipopolysaccharide (LPS) of Francisella tularensis chemically conjugated to bovine serum albumin. The results show that conjugation preserved both the antigenicity and immunogenicity of the polysaccharide moiety. Mice vaccinated with the glyco-conjugate, but not with BSA alone, were completely protected against an intradermal challenge with a highly virulent type B strain of F tularensis, and partially protected against an aerosol challenge with the same strain. However, such vaccination failed to protect against an aerosol challenge with a virulent type A strain of the pathogen. The results suggest that the O-antigen of F tularensis could be considered as a potential component of a subunit vaccine against type B, but not type A strains of F tularensis. Crown Copyright (C) 2002 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3465 / 3471
页数:7
相关论文
共 26 条
  • [1] Haemophilus influenzae type b meningitis in The Gambia after introduction of a conjugate vaccine
    Adegbola, RA
    Usen, SO
    Weber, M
    Lloyd-Evans, N
    Jobe, K
    Mulholland, K
    McAdam, KPWJ
    Greenwood, BM
    Milligan, PJM
    [J]. LANCET, 1999, 354 (9184) : 1091 - 1092
  • [2] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [3] Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
    Boutonnier, A
    Villeneuve, S
    Nato, F
    Dassy, B
    Fournier, JM
    [J]. INFECTION AND IMMUNITY, 2001, 69 (05) : 3488 - 3493
  • [4] Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults
    Cohen, D
    Ashkenazi, S
    Green, MS
    Gdalevich, M
    Robin, G
    Slepon, R
    Yavzori, M
    Orr, N
    Block, C
    Ashkenazi, I
    Shemer, J
    Taylor, DN
    Hale, TL
    Sadoff, JC
    Pavliakova, D
    Schneerson, R
    Robbins, JB
    [J]. LANCET, 1997, 349 (9046) : 155 - 159
  • [6] Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS
    Conlan, JW
    KuoLee, R
    Shen, H
    Webb, A
    [J]. MICROBIAL PATHOGENESIS, 2002, 32 (03) : 127 - 134
  • [7] CONLAN JW, UNPUB MICE INTRADER
  • [8] Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production
    Cowley, SC
    Myltseva, SV
    Nano, FE
    [J]. MOLECULAR MICROBIOLOGY, 1996, 20 (04) : 867 - 874
  • [9] DIENST F T Jr, 1963, J La State Med Soc, V115, P114
  • [10] Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon
    Dreisbach, VC
    Cowley, S
    Elkins, KL
    [J]. INFECTION AND IMMUNITY, 2000, 68 (04) : 1988 - 1996